Spectrum Pharmaceuticals seeks FDA approval for ROLONTIS to combat chemotherapy-induced neutropenia
In a significant move within the oncology sector, Spectrum Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim). This application aims to secure approval for ROLONTIS as a treatment for chemotherapy-induced neutropenia, a common and serious side effect of cancer treatment. Pivotal clinical trials underpinning […]